Biological therapy, or biological drugs, refers to monoclonal antibodies that are directed against specific targets involved in the pathogenesis of chronic inflammatory conditions. For inflammatory bowel disease (IBD), this primarily refers to:
- Anti-tumor necrosis factor (TNF) therapies (infliximab, adalimumab, certolizumab, golimumab)
- Integrin targets (natalizumab, vedolizumab), and
- Interleukin (IL)-12/23 (ustekinumab)
A Trial for Prevention of Loss of the Effect of Biological Drugs in Patients With Inflammatory Bowel Disease. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read the source article at Home – ClinicalTrials.gov
